Zealand Pharma Launches Phase 3 Trials for Obesity Drug Petrelintide…

Event summary

Zealand Pharma initiated the global Phase 3 ZUPREME program for petrelintide, a once-weekly obesity treatment.
The program includes three trials (ZUPREME-3, ZUPREME-4, ZUPREME-5) with approximately 7,000 participants.
Petrelintide demonstrated double-digit weight loss in Phase 2 trials with a tolerability profile comparable to placebo.
The trials are designed to support regulatory filings for chronic weight management.
Zealand Pharma and Roche are collaborating on the development and commercialization of petrelintide.

The big picture

The initiation of Phase 3 trials for petrelintide marks a critical step in Zealand Pharma's strategy to establish the drug as a leading therapy for obesity. The collaboration with Roche underscores the potential of petrelintide in a competitive market, where effective and tolerable weight management solutions are in high demand. The success of these trials could position Zealand Pharma as a key player in the metabolic health sector.

What we're watching

Clinical Efficacy: Whether petrelintide can sustain double-digit weight loss in larger Phase 3 trials.
Regulatory Pathway: The pace at which Zealand Pharma can secure regulatory approvals for petrelintide.
Commercial Strategy: How Zealand Pharma and Roche will position petrelintide against existing obesity treatments.